<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482635</url>
  </required_header>
  <id_info>
    <org_study_id>1368-0005</org_study_id>
    <secondary_id>2017-004230-28</secondary_id>
    <nct_id>NCT03482635</nct_id>
  </id_info>
  <brief_title>BI 655130 Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis</brief_title>
  <official_title>A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in Patients With Moderate-to-severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial has two sequentially enrolling parts with different objectives. The primary
      objectives of this trial are

        -  to prove the concept of clinical activity of BI 655130 in patients with
           moderate-to-severely active ulcerative colitis who have failed previous biologic
           treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II)

        -  to confirm efficacy and safety of BI 655130 in patients with moderate-to-severely active
           ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III)

        -  To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the
           target population to be evaluated in study 1368-0020.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Clinical Remission</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline</measure>
    <time_frame>Up to baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Proportion of patients with combined Mucosal healing and histologic remission</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Proportion of patients with Mucosal Healing</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Proportion of patients with Clinical response</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Proportion of patients with Mucosal Healing</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Proportion of patients with Clinical response</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Group 1- Placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2- Small Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3- Medium Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - High Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655130</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Group 2- Small Dose Group</arm_group_label>
    <arm_group_label>Group 3- Medium Dose Group</arm_group_label>
    <arm_group_label>Group 4 - High Dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Group 1- Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 75 years, at date of signing informed consent, males or females

          -  Diagnosis of ulcerative colitis ≥ 3 months prior to screening by clinical and
             endoscopic evidence corroborated by a histopathology report

          -  Moderate to severe activity (total MCS 6 to 12 AND mESS ≥ 2 within 7- 28 days prior to
             first dose)

          -  Endoscopic activity extending proximal to the rectum (≥ 15 cm from anal verge)

          -  Demonstrated in the past inadequate response or loss of response or have had
             unacceptable side effects with approved doses of TNFα antagonists (infliximab,
             adalimumab, golimumab) and / or vedolizumab

          -  Further inclusion criteria apply

        Exclusion Criteria:

          -  Evidence of abdominal abscess at screening

          -  Evidence of fulminant colitis or toxic megacolon at screening

          -  Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Research Center of Connecticut, LLC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Ginsburg</last_name>
      <phone>+001 (203) 281-5161</phone>
      <email>pginsburg@gastrocenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Advanced GI</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andria Mushahwar</last_name>
      <phone>+001 (321) 295-7850</phone>
      <email>amushahwar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CroNOLA, LLC</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathaniel Winstead</last_name>
      <phone>+001 (985) 601-2622</phone>
      <email>winstead@houma-gi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Wootton</last_name>
      <phone>+001 (757) 461-0165</phone>
      <email>ftwresearch@dlds.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edegem - UNIV UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Macken</last_name>
      <phone>+32 3 821 3000</phone>
      <email>Elisabeth.Macken@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Louis</last_name>
      <phone>+32 (0)4 366 72 56</phone>
      <email>Edouard.Louis@ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung Ik Jang</last_name>
      <phone>82 53 620 3830</phone>
      <email>jbi@med.yu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Il Park</last_name>
      <phone>82 2 2001 8555</phone>
      <email>diksmc.park@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hee Cheon</last_name>
      <phone>82 2 2228 1990</phone>
      <email>geniushee@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St.Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang-Moon Lee</last_name>
      <phone>82 31 249 8151</phone>
      <email>drmaloman@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

